Fig. 4From: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)Functional and structural outcomes at month 12 according to disease activity status. Functional (a–c) and structural (d–f) outcomes at month 12 according to disease activity status at months 3 and 12, based on patients with data available at baseline, month 6 and month 12. *P <0.05; †Non-significant. Disease activity states are mutually exclusive (a patient can be in only one category at any one time) and were defined as: Disease Activity Score using 28-joint counts (DAS28) remission = DAS28 <2.6; DAS28 low disease activity (LDA) = DAS28 2.6–3.2; DAS28 moderate disease activity (MDA)/high disease activity (HDA) = DAS28 >3.2; Simplified Disease Activity Index (SDAI) remission = SDAI ≤3.3; SDAI LDA = SDAI >3.3–11; SDAI MDA/HDA = SDAI >11; Clinical Disease Activity Index (CDAI) remission = CDAI ≤3.3; CDAI LDA = CDAI >2.8–10; CDAI MDA/HDA = CDAI >10. ANCOVA analysis of covariance, MTX methotrexateBack to article page